Connection

NA LI to Anti-Arrhythmia Agents

This is a "connection" page, showing publications NA LI has written about Anti-Arrhythmia Agents.
Connection Strength

1.484
  1. "Sorting" SERCA2a: A novel therapeutic strategy in heart failure? Int J Cardiol. 2018 12 01; 272:306-307.
    View in: PubMed
    Score: 0.554
  2. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. Int J Cardiol. 2017 Jan 15; 227:668-673.
    View in: PubMed
    Score: 0.489
  3. Chiral separation of racemate CPU86017, an anti-arrhythmic agent, produces stereoisomers possessing favourable ion channel blockade and less alpha-adrenoceptor antagonism. Clin Exp Pharmacol Physiol. 2008 May; 35(5-6):643-50.
    View in: PubMed
    Score: 0.265
  4. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2. Heart Rhythm. 2018 04; 15(4):578-586.
    View in: PubMed
    Score: 0.132
  5. Cardiac crises: Cardiac arrhythmias and cardiomyopathy during TANGO2 deficiency related metabolic crises. Heart Rhythm. 2022 10; 19(10):1673-1681.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.